AVITA Medical, Inc. (RCEL) has a negative trailing P/E of -2.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 8.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -36.59%, forward earnings yield 11.39%. PEG 0.06 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 28/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -3.6 | 0.22 | 8.04 | 34.86 | - |
| 2018 | -2.9 | -0.41 | 2.62 | 39.62 | - |
| 2019 | -27.8 | 0.71 | 33.50 | 127.48 | - |
| 2020 | -14.7 | -0.09 | 8.56 | 43.45 | - |
| 2021 | -15.7 | 0.51 | 3.60 | 14.24 | - |
| 2021 | -11.6 | 0.23 | 2.79 | 8.84 | - |
| 2022 | -6.2 | -0.12 | 1.95 | 4.79 | - |
| 2023 | -9.8 | 0.91 | 7.08 | 6.93 | - |
| 2024 | -5.4 | -0.08 | 73.64 | 5.16 | - |
| 2025 | -2.0 | 0.07 | -5.77 | 1.34 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.72 | $1.18M | $-11.51M | -975% |
| 2017 | $-1.85 | $1.26M | $-17.21M | -1370.8% |
| 2018 | $-2.78 | $5.47M | $-25.1M | -458.6% |
| 2019 | $-3.00 | $20.67M | $-60.9M | -294.7% |
| 2020 | $-2.07 | $14.26M | $-42.03M | -294.7% |
| 2021 | $-1.03 | $33.03M | $-25.14M | -76.1% |
| 2022 | $-1.57 | $50.56M | $-39.17M | -77.5% |
| 2023 | $-1.40 | $50.14M | $-35.38M | -70.6% |
| 2024 | $-2.39 | $64.25M | $-61.85M | -96.3% |
| 2025 | $-1.74 | $71.61M | $-48.59M | -67.8% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.00 | $-1.02 – $-0.97 | $82.41M | $75.74M – $114.28M | 4 |
| 2027 | $-0.36 | $-0.46 – $-0.25 | $118.55M | $108.97M – $164.41M | 4 |
| 2028 | $0.59 | $-0.02 – $1.20 | $167.55M | $165.88M – $169.22M | 2 |
| 2029 | $2.76 | $2.47 – $4.15 | $411.37M | $378.1M – $570.47M | 1 |
| 2030 | $3.62 | $3.24 – $5.44 | $497.55M | $457.31M – $689.97M | 1 |
